Comparison of the onset of H1-antagonism with acrivastine and terfenadine by histamine bronchial challenge in volunteers.
The speed of onset of H1-antagonism by 8 mg acrivastine and 60 mg terfenadine was compared by bronchial challenge of volunteers with histamine. Active treatments or placebo were administered 1 or 2 h before challenge in a double-blind, randomized, balanced crossover manner to 10 subjects. Acrivastine and terfenadine significantly attenuated the response to inhaled histamine compared to placebo. The effects of acrivastine at 1 and 2 h before challenge, and terfenadine at 2 h were indistinguishable, but that of terfenadine at 1 h was significantly less, indicating that acrivastine has a faster onset of action than terfenadine.
Rolan
P E
PE
Human Pharmacology Unit, Wellcome Research Laboratories, Beckenhan, UK.
Adams
J
J
Posner
J
J
D000328:Adult; D000336:Aerosols; D001559:Benzhydryl Compounds / Q000494:pharmacology*; D005260:Female; D005541:Forced Expiratory Volume; D006632:Histamine / Q000008:administration & dosage; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000502:physiology*; D008297:Male; D011725:Pyridines / Q000494:pharmacology*; D011969:Receptors, Histamine H1 / Q000187:drug effects*; D016593:Terfenadine; D014311:Triprolidine / Q000031:analogs & derivatives / Q000494:pharmacology*; D014797:Vital Capacity / Q000187:drug effects
D000336:Aerosols; D001559:Benzhydryl Compounds; D006634:Histamine H1 Antagonists; D011725:Pyridines; D011969:Receptors, Histamine H1; D014311:Triprolidine; D016593:Terfenadine; D006632:Histamine; C043648:acrivastine